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Abstract
Seven-transmembrane receptors are commonly coupled to multiple signaling pathways in cells. The
simple model describing agonists for these receptors as producing a common active state to induce
uniform activation of the pathways linked to the receptor has been shown to be untenable in light of a
large body of data that suggest that some agonists produce activation of some but not all available
pathways. These agonists are referred to as ‘biased’ in that they select which signaling pathways
become activated upon binding to the receptor. The data to support this mechanism as well as ideas
on the possible therapeutic application of this effect will be discussed.
Introduction and context
Seven-transmembrane receptors are a family of signaling
proteins that bind hormones, autacoids, and neurotrans-
mitters to mediate a myriad of cellular functions. Like all
proteins, these exist in collections of tertiary conforma-
tions called protein ensembles; receptors sample these
conformations according to changes in the thermal
energy in the system. Some of these conformations can
be designated as ‘active states’, denoting their ability to
activate cytosolic signaling mechanisms. The current
model of pharmacological seven-transmembrane recep-
tor agonism describes the selective binding of agonists
to these active states to enrich their presence within the
ensemble through a process referred to as ‘conforma-
tional selection’ [1]. Thus, through Le Chatelier’s
principle, upon agonist binding, the make-up of the
ensemble is directed toward the conformations posses-
sing the highest affinity for the agonist and these are
stabilized at the expense of other conformations. The
product of this thermodynamic process is a collection of
membrane proteins that activate cellular signaling
processes and agonism ensues. Early discussions of this
mechanism and agonist efficacy in general used the most
simple assumptions that the receptor is the minimal unit
of control for this process and that a receptor activated by
any agonist triggers all cellular signaling processes
mediated by that particular receptor type.
Two experimental findings required the modification of
this idea. First, it was observed that seven-transmem-
brane receptors pleiotropically interact with a wide
range of cytosolic coupling proteins. Second, new
technology revealed multiple biochemical behaviors of
receptors such as the propensity to be phosphorylated
and to interact with multiple G-proteins and b-arrestin,
internalization, and desensitization. Subsequent studies
have indicated that not all agonists uniformly produce
activation of these multiple receptor behaviors. For
example, the peptides PACAP1-27 and PACAP1-38
activate PACAP (pituitary adenylate cyclase-activating
polypeptide type 1) receptors to elevate cyclic AMP and
increase production of IP3. However, the relative
potency of these agonists for these responses is reversed;
the relative efficacy of PACAP1-27 for cyclic AMP
elevation is higher than that of PACAP1-38 but lower
for elevation of IP3 [2]. This indicates that the receptor
is not the minimal unit of control of agonism, it is the
agonist-receptor complex that controls the ultimate
signaling event; the data leading to this conclusion also
clearly indicate that agonist activation of multiple
signaling mechanisms is not uniform but rather is
often ‘biased’ toward some but not all signaling
pathways. This concept has been put into a formal
model showing that agonist-selective states can produce
biased agonism [3].
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two additional factors are relevant to the discussion,
namely the nature of the receptor-active state and the
interaction of the activated receptor with multiple
cytosolic signaling proteins. The selective activation of
cellular pathways with biased agonists is consistent with
there being ‘agonist-specific’ ensembles of receptor
conformations mediating these events; subsequent
studies have given independent corroboration of this
mechanism through separate lines of experimentation
that directly show that ligands can stabilize unique
receptor conformations [4-9]. Similarly, molecular
dynamics predicts that when proteins such as receptors
change conformation, different regions of the receptor
change independently (i.e., the protein does not form
uniform global conformations) [10-13]. Therefore, the
fact that signaling proteins interact with different regions
of the receptor (e.g. [14,15]) suggests that different
conformations would not produce uniform coupling to
all signaling proteins; that is, the unique receptor
conformations stabilized by agonists most likely will
result in differential (biased) activation of cell signaling
pathways [16]. In fact, the activation of a receptor that
interacts with multiple signaling components in a cell
most likely will never produce equal activation of all
pathways; therefore, from this standpoint, every agonist
will have a bias in signaling. However, a useful point of
reference is the natural agonist for the receptor; this will
have a natural signaling bias and can be used as a
standard with which other agonists can be compared.
Within this scale, functionally selective agonists are
defined as having a signaling bias different from that of
the natural agonist.
Major recent advances
Studies using a wide variety of technologies now indicate
that biased agonism is a common phenomenon.
Agonists have been shown to differentially activate
different G-proteins and b-arrestin and have differing
susceptibility to phosphorylation, desensitization, and
internalization in a wide variety of receptor systems
(for reviews, see [17-23]). In particular, many studies
now specifically show how differential activation of
G-proteins versus b-arrestin results from biased stabiliza-
tion of receptor conformation [24,25]. Observed most
often with synthetic agonist ligands, bias can also be
detected in natural systems such as the chemokine CCR7
receptor. Thus, CCL19 and CCL21, two natural agonists
for the CCR7 chemokine receptor, differ in the type of
pathway stimulation they elicit; although both agonists
produce G-protein activation, only CCL19 (not CCL21)
causes receptor agonist-dependent phosphorylation and
recruitment of b-arrestin to terminate the G-protein
stimulus [26]. In addition to G-proteins and b-arrestin,
seven-transmembrane receptors have been shown to
couple to many other signaling proteins such as JAK/
STATs (Janus kinase/signal transducers and activators of
transcription), Src-family tyrosine kinases, G-protein
receptor kinases (GRKs), and PDZ domain-containing
proteins [27]. Finally, other receptor types also are
involved in biased signaling. For example, different
proteases have been shown to differentially activate
protease-activated receptors through stabilization of
distinct conformation (much like biased ligands [28]).
The discovery that some ligands can produce activation
of some but not all receptor-linked stimulus mechanisms
can introduce ambiguity in the classification of drugs
[29]. For instance, the active internalization of receptors
by some antagonists indicates that a label of ‘agonist’
should be placed on this one aspect of receptor behavior
(internalization) [17,30,31]. Similarly, while proprano-
lol is a well-known antagonist and inverse agonist of
agonist activation of Gs-coupled effects of b-adrenocep-
tors [32], it has also been shown to be an active activator
(agonist) of extracellular signal-regulated kinase (ERK)
[33]. Biased agonism can be complex and need not
necessarily involve excitatory signaling events; that is,
some ligands can be positive agonists for one pathway
and antagonists or inverse agonists for another [34].
Such divergences in efficacy have been used to propose
that efficacy be considered ‘pluridimensional’; that is,
ligands may have a range of different efficacies to cause a
range of receptor behaviors [35].
Future directions
The therapeutic relevance of biased agonism is still
unknown. The emphasis has clearly shifted from ‘does
biased agonism occur?’ to ‘when it does occur, how can it
be harnessed therapeutically?’ This trend is consistent
with the improving technology to detect whole-cell
effects through label-free technology; these data provide
cell-specific and detailed information regarding signaling
patterns of ligands [36-40]. Thus, while assay technology
is making it increasingly possible to detect and char-
acterize agonist bias, focus is shifting to the mechanisms
responsible for this effect.
Emphasis has also shifted from the cell surface to the
cytosol in an effort to understand biased signaling. For
example, detailed studies of biased ligand-induced
b-arrestin-mediated signaling indicate significant differ-
ences in functionally distinct pools of b-arrestin accessed
through conformational control of receptor sensitivity to
phosphorylation by GRK isoforms [41]. These unique
phosphorylation patterns result in effective ‘bar coding’
of ligand-bound receptors that lead to further down-
stream instruction of b-arrestin partners within the
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conformations to achieve selective signaling, it has now
been shown that b-arrestin itself forms different con-
formations and that these are associated with selective
functions within the cell [42].
The significance of biased signaling is increasingly
appreciated as signaling pathways become linked to
normal physiology and pathophysiology. For example,
the reported ERK activation through b-arrestin by some
antagonists (i.e. propranolol [33]) is interesting in light
of recent data that suggest that angiotensin receptor-
mediated b-arrestin stimulation may be beneficial in the
treatment of heart failure [43] or, alternatively, may be
linked to the progression of heart failure through
aldosterone pathways [44]. Biased signaling has been
implicated in a unique profile of antagonism and
agonism in breast cancer. Specifically, substance-P
analogues SP-D and SP-G have been shown to produce
biased signaling at vasopressin V1A receptors and
receptors for gastrin-releasing peptide to yield a profile
of blocked Gq-protein-mediated calcium release and
concomitant activation of ERK. This is postulated to
produce a unique antiproliferative profile of activity
[45].
In terms of specific examples in which bias may be a
practical aspect of drug activity, there are interesting
divergences in activity for opioid agonists to produce
analgesia with reduced propensity to produce desensiti-
zation and d-opioid receptor internalization [46-50] and
intriguing functionally selective dopamine [51] and
serotonin [52,53] agonists for the treatment of psychia-
tric disorders. Similarly, there are data that suggest that
functionally selective thyrotropin agonists may be able
to differentiate thyroid growth and thyroid hormone
synthesis [54] and orexin receptor functionally selective
agonists may differentiate effects on catecholamine
release and adrenal steroid production [55,56]. The
consequences of biased agonism currently are an intense
subject of study. While initial work in the field
considered acute effects such as desensitization, receptor
internalization, and differential activation of G-proteins,
more recent studies center on long-term effects of biased
signaling such as prolonged signaling through b-arrestin
activation and effects such as G-protein regulation [57].
In general, it is not yet clear to what extent these biased
stimulations of cellular signaling pathways will yield
favorable therapeutic phenotypic agonism. What is clear
is that seven-transmembrane receptors cannot be con-
sidered on/off switches and synthetic agonists cannot be
considered surrogates of natural agonists. Stabilization
of receptor-active states by different molecules has the
potential to traffic receptor stimulus in unique ways to
cause complex patterns of cellular activation. The
challenge now is to harness this powerful effect.
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